Sponsor Pipeline

Nanjing Sanhome Pharmaceutical, Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
2
Phase 3
7
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 2/3
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06080776 SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With… Non-small Cell Lung Cancer Recruiting
Phase 2/3
NCT07392866 A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the… Hepatocellular Carcinoma (HCC) Not Yet Recruiting
Phase 1
NCT07390838 A Study of SH009 Injection in Patients With Advanced Solid Tumors. Liver Cancer (Locally Advanced or Metastatic) Recruiting
NCT07362264 A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors Liver Cancer Active, Not Recruiting
NCT07557004 A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2… HR+ / HER2- Advanced Breast Cancer Active, Not Recruiting
Disease Areas
Get alerts when Nanjing Sanhome Pharmaceutical, Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free